Albino Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 5.30 Cr
- Paid Up Capital ₹ 2.57 Cr
- Company Age 33 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 36.21 Cr
- Satisfied Charges ₹ 29.57 Cr
- Revenue Growth 16.28%
- Profit Growth 19.10%
- Ebitda 29.13%
- Net Worth 18.45%
- Total Assets -1.05%
About Albino Lifesciences
Albino Lifesciences Private Limited (ALPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 26 April 1991 and has a history of 33 years and nine months. Its registered office is in New Delhi, Delhi, India.
The Corporate was formerly known as Impex Pharma Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.30 Cr and a paid-up capital of Rs 2.57 Cr.
The company currently has active open charges totaling ₹36.21 Cr. The company has closed loans amounting to ₹29.57 Cr, as per Ministry of Corporate Affairs (MCA) records.
Sugandha Daga and Dinesh Daga serve as directors at the Company.
Company Details
- Location
New Delhi, Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U74899DL1991PTC044094
- Company No.
044094
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Apr 1991
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Albino Lifesciences?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dinesh Daga  | Managing Director | 26-Apr-1991 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sugandha Daga | Director | 07-Feb-2011 | Current |
Financial Performance of Albino Lifesciences.
Albino Lifesciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 16.28% increase. The company also saw a substantial improvement in profitability, with a 19.1% increase in profit. The company's net worth Soared by an impressive increase of 18.45%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Albino Lifesciences?
In 2023, Albino Lifesciences had a promoter holding of 100.00%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Wembrace Biopharma Private LimitedSugandha Daga and Dinesh Daga are mutual person
Avish Bio-Systems LlpSugandha Daga is a mutual person
- Avish Life Sciences Private Limited
Sugandha Daga is a mutual person
Charges (Loans)
₹36.21 Cr
₹29.57 Cr
Charges Breakdown by Lending Institutions
- Axis Bank Limited : 22.00 Cr
- Others : 14.21 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 13 Jun 2023 | Others | ₹12.21 Cr | Open |
| 09 Dec 2021 | Others | ₹2.00 Cr | Open |
| 28 Aug 2020 | Axis Bank Limited | ₹22.00 Cr | Open |
| 27 Apr 2022 | Axis Bank Limited | ₹7.45 Cr | Satisfied |
| 29 Jan 2021 | Others | ₹1.50 Cr | Satisfied |
How Many Employees Work at Albino Lifesciences?
Albino Lifesciences has a workforce of 22 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Albino Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Albino Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
